These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19885836)

  • 1. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.
    Trent JC; Patel SS; Zhang J; Araujo DM; Plana JC; Lenihan DJ; Fan D; Patel SR; Benjamin RS; Khakoo AY
    Cancer; 2010 Jan; 116(1):184-92. PubMed ID: 19885836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
    Perik PJ; Rikhof B; de Jong FA; Verweij J; Gietema JA; van der Graaf WT
    Ann Oncol; 2008 Feb; 19(2):359-61. PubMed ID: 17962203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure during imatinib mesylate treatment.
    Turrisi G; Montagnani F; Grotti S; Marinozzi C; Bolognese L; Fiorentini G
    Int J Cardiol; 2010 Nov; 145(1):148-50. PubMed ID: 19656583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
    Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors.
    Yachoui R
    Am J Ther; 2014; 21(5):e148-50. PubMed ID: 23567788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumor (GIST) and imatinib.
    Kubota T
    Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
    Pariente A; Etcharry F; Cales V; Laborde Y; Ferrari S; Biour M
    Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):785-7. PubMed ID: 16772838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
    Schlemmer M; Bauer S; Schütte R; Hartmann JT; Bokemeyer C; Hosius C; Reichardt P
    Eur J Med Res; 2011 May; 16(5):206-12. PubMed ID: 21719393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management.
    Kim KW; Shinagare AB; Krajewski KM; Pyo J; Tirumani SH; Jagannathan JP; Ramaiya NH
    Korean J Radiol; 2015; 16(2):304-13. PubMed ID: 25741192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.
    Akasbi Y; Arifi S; Brahmi SA; El Mrabet FZ; Mellas N; Mernisi FZ; El Mesbahi O
    J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():71-3. PubMed ID: 24006243
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
    Tonyali O; Coskun U; Yildiz R; Karakan T; Demirci U; Akyurek N; Benekli M; Buyukberber S
    Med Oncol; 2010 Sep; 27(3):768-73. PubMed ID: 19662540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event.
    Liu H; Liao G; Yan Z
    BMC Gastroenterol; 2011 Nov; 11():116. PubMed ID: 22047550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
    Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
    Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA
    BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.